Australia markets closed
  • ALL ORDS

    7,063.10
    -48.30 (-0.68%)
     
  • AUD/USD

    0.7737
    -0.0008 (-0.11%)
     
  • ASX 200

    6,782.00
    -42.70 (-0.63%)
     
  • OIL

    52.87
    +0.26 (+0.49%)
     
  • GOLD

    1,845.80
    -5.10 (-0.28%)
     
  • BTC-AUD

    41,038.20
    -349.52 (-0.84%)
     
  • CMC Crypto 200

    639.14
    -0.78 (-0.12%)
     

Abbott Laboratories Beats on Q2 Estimates, But Stock Slides

Eric Volkman, The Motley Fool
·2-min read
Abbott Laboratories Beats on Q2 Estimates, But Stock Slides

Although it's popular as a coronavirus stock these days, Abbot Laboratories (NYSE: ABT) nevertheless is struggling with other areas of its business. On average, they believed Abbott would take in $6.81 billion in sales and post an adjusted net profit of $0.42 per share. Two of the company's four business lines -- its largest, medical devices, and established pharmaceuticals -- saw notably lower sales during the quarter, falling a respective 21% and nearly 9%.